93 related articles for article (PubMed ID: 2934069)
1. Influence of ciprofloxacin on the ultrastructure of gram-negative and gram-positive bacteria.
Voigt WH; Zeiler HJ
Arzneimittelforschung; 1985; 35(10):1600-3. PubMed ID: 2934069
[TBL] [Abstract][Full Text] [Related]
2. Influence of the cell wall on ciprofloxacin susceptibility in selected wild-type Gram-negative and Gram-positive bacteria.
Berlanga M; Montero MT; Hernández-Borrell J; Viñas M
Int J Antimicrob Agents; 2004 Jun; 23(6):627-30. PubMed ID: 15194135
[TBL] [Abstract][Full Text] [Related]
3. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
Zeiler HJ
Drugs Exp Clin Res; 1985; 11(5):335-8. PubMed ID: 2941261
[TBL] [Abstract][Full Text] [Related]
4. Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria.
Chin NX; Neu HC
Am J Med; 1987 Apr; 82(4A):58-62. PubMed ID: 3578330
[TBL] [Abstract][Full Text] [Related]
5. [In vitro antibacterial activity of ciprofloxacin against uropathogenic organisms].
Allocati N; Catamo G; Cellini L
Boll Soc Ital Biol Sper; 1984 Oct; 60(10):1927-33. PubMed ID: 6440583
[TBL] [Abstract][Full Text] [Related]
6. Experience with ciprofloxacin in vitro and in vivo.
Giamarellou H; Efstratiou A; Tsagarakis J; Petrikkos G; Daikos GK
Arzneimittelforschung; 1984; 34(12):1775-8. PubMed ID: 6442151
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the in vitro and in vivo activity of ciprofloxacin measured against current standards of therapy.
Zeiler HJ; Metzger KG; Schacht P; Grohe K
Drugs Exp Clin Res; 1985; 11(5):343-50. PubMed ID: 2941263
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric viability assessment and transmission electron microscopic morphological study of bacteria in glycerol.
Saegeman VS; De Vos R; Tebaldi ND; van der Wolf JM; Bergervoet JH; Verhaegen J; Lismont D; Verduyckt B; Ectors NL
Microsc Microanal; 2007 Feb; 13(1):18-29. PubMed ID: 17234033
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of norfloxacin against gram-positive and gram-negative organisms from recent clinical isolates].
Mancini C; Brenciaglia MI; Ghezzi MC; Giordano A; Nazzari C; Cipriani P
Boll Ist Sieroter Milan; 1985; 64(4):289-93. PubMed ID: 3935135
[TBL] [Abstract][Full Text] [Related]
10. Sub-inhibitory and post-antibiotic effects of an optically active isomer of ofloxacin.
Tanaka M; Une T; Osada Y
Arzneimittelforschung; 1989 Jul; 39(7):750-4. PubMed ID: 2506868
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
12. [Distribution of pathogen and resistance of nosocomial infections in the intensive care units].
Dai CM; Zhou JD; Wu Y; Qi Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Apr; 31(2):277-80. PubMed ID: 16706133
[TBL] [Abstract][Full Text] [Related]
13. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
Cetinkaya E; Coban AY; Durupinar B
Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
[TBL] [Abstract][Full Text] [Related]
14. Aerobic bacteria isolated from blood cultures of patients and their antibiotic susceptibilities in Harare, Zimbabwe.
Obi CL; Mazarura E
Cent Afr J Med; 1996 Dec; 42(12):332-6. PubMed ID: 9164012
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of some heterocyclic derivatives.
Alsaleh FS; Gamal el-Din AY; Kandeel EM
Microbios; 1995; 82(331):87-93. PubMed ID: 7609663
[TBL] [Abstract][Full Text] [Related]
16. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
Kim SY; Lim JA; Choi JS; Choi EC; Joo CK
Cornea; 2007 Jul; 26(6):720-5. PubMed ID: 17592324
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.
Chalkley LJ; Koornhof HJ
Antimicrob Agents Chemother; 1985 Aug; 28(2):331-42. PubMed ID: 2939797
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory and bactericidal activities of amifloxacin, a new quinolone carboxylic acid, compared with those of seven other antimicrobial agents.
Baltch AL; Sutphen NT; Smith RP; Conley PE
Clin Ther; 1984; 7(1):73-80. PubMed ID: 6440708
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
[TBL] [Abstract][Full Text] [Related]
20. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
Zhao X; Quinn B; Kerns R; Drlica K
J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
